| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802352701028 | 235270102 | XEFO F.C.TAB 4MG/TAB BTx20(BLIST 2x10) | 1.56 | 1.64 | 2.26 |
| 05/2018 | 2802352703015 | 235270301 | XEFO PS.INJ.SOL 4MG/1ML(8MG/VIAL) BTx 1 VIAL (8 R) +1 AMP x 2 ML SOLVENT +1 AMP x 2 ML SOLVENT | 1.82 | 1.91 | 2.63 |
| 05/2018 | 2802352704036 | 235270403 | XEFO (RAPID) F.C.TAB 8MG/TAB BTx30(BLIST 3x10) | 4.28 | 4.49 | 6.19 |
For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
Like other NSAIDS, lornoxicam's anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined.
Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).
3-5 hours